GU14-182
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182
Linked In
You Tube
Completed Trials
Bladder
GU15-215
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
HCRN-GU15-217
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
HCRN-GU15-262
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
GU17-295
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
HCRN-GU17-294
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients with Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
BTCRC-GU16-051
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
GU12-160
The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
GU12-157
A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157
GU10-148
Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148
GU10-147
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147.
GU07-123
Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder
GU07-122
A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
GU04-75
A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75
Breast
HCRN-BRE19-433
A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)
BRE12-158
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.
TBCRC029
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
TBCRC035
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
BTCRC-BRE15-016
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
BRE09-146
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
BRE07-126
A Phase II Study of Lonafarnib in Patients with Locally advanced and Metastatic Breast Cancer: Hoosier Oncology Group: BRE07-126
BRE06-120
A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team
BRE06-109
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109
BRE05-97
A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen
BRE04-80
A Phase I/II Study of PTK787 in Combination with Trastuzumab in Patients with Newly Diagnosed HER-2 Overexpressing Locally Recurrent or Metastatic Breast Cancer
BRE03-61
A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer
BRE03-60
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
BRE02-43
A Pilot Trial Incorporating ZD1839 (IRESSA®) into Adjuvant Therapy for Breast Cancer
BRE00-10
Phase I/II Trial of Chronic Low Dose Epirubicin and SU5416 in Patients with Previously Untreated Metastatic Breast Cancer
BRE99-1
Phase II Trial of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: a Hoosier Oncology Group Trial
BRE98-1
Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer, Hoosier Oncology Group BRE98-1
BRE96-1
Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer
BRE94-1
A Hoosier Oncology Group Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial BRE94-1
BRE93-1
A Phase II Study of Oral Etoposide and Ifosfamide in the Treatment of Patients with Stage IV Breast Cancer
BRE92-1
A Phase III Study of Pre-Operative Chemotherapy, Cytoxan, Adria, 5-FU vs HD Adria, Cytoxan and G-CSF for Breast Cancer not Considered Candidates for Lumpectomy
BRE89-1
Carboplatin and WR-2721 as First-Line Chemotherapy for Metastatic Breast Cancer (MBC): A Hoosier Oncology Group Study BRE89-1
COE-05
A Retrospective Analysis of Proteomic, Genomic, and Pharmacogenetics in Patients Receiving Systemic Chemotherapy for Locally Advanced or Metastatic Breast Cancer
COE-03
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
COE-02
Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
COE-01
Department of the Army, US Army Medical Research Acquisition Activity: Center of Excellence for Individualization of Therapy for Breast Cancer: Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
HOG-09
Phase II Study of Methotrexate, Vinblastine Adriamycin and Cisplatin (M-VAC) Combination Chemotherapy for Previously Untreated or Minimally Treated Advanced Adenocarcinoma of the Breast
HOG-07
A Prospective Randomized Controlled Study of Adjuvant Chemotherapy (Cytoxan, Methotrexate, 5-Fluorouracil, Vincristine, Prednisone) vs. No Therapy in Women with ER Negative and Axillary Lymph Node Negative Breast Cancer
HOG-04
Phase III Study of Megace vs Aminoglutethimide + Hydrocortisone in Previously Treated Hormonally Responsive Metastatic Breast Cancer
TBCRC12-142
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Carcinoma of Unknown Primary
Cervical
GYN97-2
A Phase II Trial of Pre-operative Pelvic and Para-Aortic Radiotherapy and Radical Pelvic Surgery in Stages IIIB and IVA Carcinoma of the Cervix
Cholangiocarcinoma
Colorectal
GI14-191
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy with Ginseng for Patients on Treatment with Regorafenib: HCRN GI14-191.
GI14-186
A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186
GI05-102
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
GI00-2
A Phase II Trial of Irinotecan (CPT-11), 5-Fluorouracil (5-FU), Glutamine, Leucovorin and Celecoxib as First Line Therapy for Metastatic Colorectal Cancer –GI00-2
GI89-1
A Randomized Phase III Study of 5-Fluorouracil vs 5-Fluorouracil + Levamisole in Previously Untreated Metastatic Colon Cancer – GI89-1
HOG-05
Adjuvant Internal Radiotherapy to the Liver Using Colloidal 32p in Colon Cancer
HOG-01
A Randomized Phase III Study of 5-FU + Cisplatin in Previously Untreated Metastatic Adenocarcinoma of the Colon
Endometrial
BTCRC-GYN15-013
Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
Esophageal
HCRN-ESO17-325
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
BTCRC-GI18-149
Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
GI06-112
A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer
GI05-92
A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92)
GI02-38
A Phase II Study of Capecitabine plus Docetaxel Combination in Patients with Esophageal/Gastric Cancer
Gastric
HCRN-ESO17-325
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
GI17-319
A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinoma
BTCRC-GI15-015
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-015
Status: Closed to Accrual
BTCRC-GI18-149
Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Gastroesophageal Junction
HCRN-ESO17-325
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
BTCRC-GI18-149
Phase II Study of the Combination of Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Germ Cell Tumors
Head and Neck
HN96-1
A Phase II Trial of Doxil in Advanced or Recurrent Head and Neck Cancer
HN02-40
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Kidney
BTCRC-GU16-043
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
HCRN GU17-289
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)
GU15-223
Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223
HCRN-GU17-326
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
BTCRC-GU14-003
Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
GU09-145
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
GU96-1
A Phase II Trial of Doxil in the Treatment of Advanced Renal Cell Cancer
GU91-1
A Phase II Study of Altretamine (HEX) for the Treatment of Metastatic Renal Cell Cancer
HOG-13
Phase II Study of High-Dose Cimetidine for Treatment of Metastatic Renal Cell Carcinoma
Leukemia
BTCRC-HEM17-092
Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
BTCRC-AML18-342
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342
For full description, see clinicaltrials.gov, study #NCT04128020
CLL03-59
A Phase II Study of Ontak in Patients with Previously Treated Chronic Lymphocytic Leukemia
HOG-06
A Randomized Phase III Study of Low-Dose Cytosine Arabinoside vs Supportive Care in the Treatment of Preleukemia
Liver and Bile Duct
HCRN-GI15-225
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
HCRN GI16-263
A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263
HCRN-GI19-405
A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
BTCRC-GI13-002
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Lung
HCRN LUN17-302
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302
LUN17-126
Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients
For full description, see clinicaltrials.gov, study #NCT04470674
HCRN-LUN14-179
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
HCRN LUN17-321
A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
HCRN LUN15-233
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous, Non-squamous or Not Otherwise Specified NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
HCRN-LUN19-427
Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated, Asymptomatic Brain Metastases (HCRN LUN19-427)
Learn more:
BTCRC-LUN15-017
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy
BTCRC-LUN15-029
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
BTCRC-LUN17-139
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
BTCRC-LUN17-127
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
HCRN LUN13-175
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): HCRN LUN13-175
LUN08-129
Phase II Study of Concurrent Pemetrexed and Radiation for Stage III Non-Small Cell Lung Cancer
LUN07-130
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
LUN06-116
Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
LUN06-113
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
LUN06-107
A Phase II Trial of Concurrent Cisplatin/ Etoposide/ Radiotherapy Followed by Consolidation Sorafenib in Patients with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC)
LUN05-99
Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study
LUN04-79
A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79
LUN04-78
Pemetrexed (Alimta) in Patients with Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
LUN04-77
A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer
LUN02-50
A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)
LUN02-29
A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers
LUN01-25
Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination with Carboplatin-Paclitaxel in Patients with Chemo-therapy Naïve Advanced Non Small Cell Lung Cancer
LUN01-24
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24
LUN01-15
A Phase III Randomized Study of Taxotere 75/mg/M2 vs. ALIMTA for Second-line Chemo for Non-Small Cell Lung Cancer
LUN00-12
A Randomized, Phase III Trial Comparing CPT-11/ Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive Small-Cell Lung Cancer
LUN98-1
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
LUN97-1
A Phase II Study of Taxol + Carboplatin + Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
LUN96-2
A Phase II Study of Carboplatin plus Gemcitabine in Metastatic Non-Small Cell Lung Cancer
LUN96-1
A Phase II Study of Paclitaxel (3-Hour Infusion and Bolus Doxorubicin in Recurrent or Refractory Small Cell Lung Cancer
LUN95-1
A Phase III Study of Gemcitabine +Cisplatin vs Cisplatin Alone in Patients with Metastatic Non-Small Cell Lung Cancer
LUN93-3
A Phase II Study of VP-16 plus Ifosfamide plus Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer
LUN93-2
A Phase III Trial of Maintenance Daily Oral VP-16 vs no Further Therapy Following Induction Chemotherapy with VP-16 plus Ifosfamide plus Cisplatin (VIP) in Extensive Small Cell Lung Cancer
LUN91-1
A Randomized Phase III Study of Definitive Radiation Therapy with or without Hydroxyurea in Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer
LUN90-1
Phase II Trial of Carboplatin plus Interferon Alpha-2a in Advanced Non-Small Cell Lung Cancer
LUN89-1
Phase II Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) as Combination Chemotherapy for Previously Treated Small Cell Lung Cancer
LUN88-4
Phase II Trial of Daily Oral Etoposide in Refractory Small Cell Lung Cancer
LUN88-3
Phase III Study of VP-16 + Cisplatin Alone (VP) + Ifosfamide (VIP) for Previously Untreated Extensive Small Cell Lung Cancer
LUN87-1
A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer
LUN86-1
A Randomized Phase III Study Of Definitive Radiation Therapy With/Without Cisplatinum in Previously Untreated Inoperable Non-Metastatic Non-Small Cell Lung Cancer
HOG-14
Phase II Study of Vinblastine VP-16 (Etoposide), and Cisplatin (VEP) for Patients with Extensive Non-Small Cell Lung Cancer
HOG-12
A Phase II Trial of VP-16 and Split-Dose Cisplatin in Extensive Small Cell Lung Cancer
HOG-11
Phase III Study of Split Dose Cisplatinum Plus VP-16 in the Treatment of Locally Recurrent or Metastatic Non-Small Cell Lung Cancer
HOG-03
A Randomized Phase III Study of Variable Length of Treatment on Survival and Duration of Remission in Small Cell Lung Cancer
Lymphoma
BTCRC-HEM15-028
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL): Big Ten Cancer Research Consortium BTCRC-HEM15-028
BTCRC-HEM16-085
Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
BTCRC-LYM17-145
Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145
LYM08-134
Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
LYM03-64
A Phase II Study of Rituximab and Gemcitabine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NHL01-27
Phase I/II Study of CHOP plus Ontak, an Interleukin-2 Fusion Toxin for Patients with Peripheral T-cell Non-Hodgkin’s Lymphomas
NHL00-1
A Phase II Study of Single Agent Gemcitabine In Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin’s Lymphoma
NHL92-1
Phase II Trial of Vincristine, Prednisone, Etoposide and Mitoxantrone in Elderly Patients with Aggressive Histology in Non-Hodgkin’s Lymphoma
NHL88-1
Phase II Trial of Carboplatin in Low-Grade Non-Hodgkin’s Lymphoma
HOG-08
Phase III Study of Treatment for Aggressive Non-Hodgkin’s Lymphoma – MACOP-B vs CHop
Melanoma
MEL16-261
MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma
MMP-MEL18-372
Phase 1B/2 Study of PAC-1 and Entrectinib for Patients with Metastatic Uveal Melanoma
MEL91-1
A Phase III Study Comparing Cisplatin, Dacarbazine, Carmustine and Tamoxifen vs Dacarbazine Alone in Patients with Advanced Melanoma
MEL90-1
Phase II Trial of Carboplatin plus Interferon Alpha-2a in Metastatic Melanoma
HOG-10
Phase II Study of Cimetidine in Patients with Metastatic Malignant Melanoma
Mesothelioma
HCRN-LUN15-299
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma: Hoosier Cancer Research Network LUN15-299
Mutiple Myeloma
MM08-141
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
MM02-35
A Phase II Study of Bisphosphonate: Zoledronic Acid (Zometa) in the Management of Asymptomatic/Early Stage Multiple Myeloma
MM01-21
A Phase II Study of Daily Thalidomide, Oral Cytoxan and Prednisone for Relapsed or Refractory Multiple Myeloma
MM91-1
A Phase I/II Study of Carboplatin plus Interferon Alpha-2b in Untreated Multiple Myeloma
Myelodysplastic Syndromes
Neuroendocrine Tumors
BTCRC-GI19-400
Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400
Ovarian
GYN10-149
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149
GYN06-111
A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis
GYN06-106
A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer
Pancreatic
HCRN GI21-499
A Phase Ib/II Study of Sotorasib Combined with Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer
HCRN GI14-198
Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
GI00-11
A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients with Localized Unresectable Pancreatic Cancer
GI99-1
A Phase II Study of Gemcitabine and Docetaxel in Combination for Advanced Pancreatic Cancer
GI98-1
Phase I/II Study of Gemcitabine and Docetaxel in Combination for Unresectable or Metastatic Pancreatic Cancer – GI98-1
Prostate
BTCRC-GU19-404
A Single Arm, Phase I/II Trial of Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with Localized, High Risk Prostate Cancer Big Ten Cancer Research Consortium BTCRC-GU19-404
GU14-202
Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer with Enzalutamide and the Poly (ADP-Ribose) Polymerase [PARP] Inhibitor Niraparib.
GU13-170
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170.
GU12-159
The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159
GU07-124
A Phase II Study of Neoadjuvant Dasatinib plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
GU03-67
A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67
GU02-41
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy
GU00-9
A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer
GU98-1
Phase II Study of Vinorelbine plus Estramustine in Metastatic Hormone-Refractory Prostate Cancer
GU97-1
Phase II Study of Diethylstilbestrol in Metastatic Prostate Cancer
GU93-1
A Phase III Study of Vinblastine vs Vinblastine plus Estramustine for Metastatic Hormone Refractory Prostatic Cancer
GU90-2
Phase II Study of Flutamide Plus Interferon Alpha-2b in Metastatic Hormone Resistant Prostate Cancer
HOG-02
Phase III Randomized Comparison of Cyclophosphamide vs Cyclophosphamide + Adriamycin + Methotrexate for Stage IV Hormone Resistant Prostatic Cancer
Quality of Life
QL12-153
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
QL05-37
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
QL03-70
Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting
QL02-45
Increasing Screening in Families with Colorectal Cancer
QL02-44
Enhancing Connections: Helping the Mother with Breast Cancer Support Her Child
QL01-26
A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy
QL01-22
Predictors of Quality of Life After Treatment for Colorectal Cancer
QL00-4
A Phase I Trial of Olanzapine (Zyprexa) For the Prevention of Delayed Emesis In Cancer Patients Receiving Chemotherapy
QL97-1
Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Randomized, Double-Blind, Placebo-Controlled Trial
HOG89-1
Carboplatin in Hypercalcemia
Rectal
Sample Collection
Sarcoma
SAR90-1
Phase II Trial of Daily Oral Etoposide in Advanced Sarcoma
Urothelial Carcinoma
GU14-182
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182
GU15-215
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
HCRN-GU15-217
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
HCRN-GU15-262
Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
GU17-295
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
HCRN-GU17-294
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter